Resverlogix Corp
TSX:RVX

Watchlist Manager
Resverlogix Corp Logo
Resverlogix Corp
TSX:RVX
Watchlist
Price: 0.04 CAD Market Closed
Market Cap: 11.3m CAD

Resverlogix Corp
Investor Relations

Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.

Show more
Loading
RVX
S&P TSX Composite Index (Canada)

Earnings Calls

No Earnings Calls Available

Management

Mr. Aaron Bradley Cann C.A., CPA, CBV
Chief Financial Officer
No Bio Available
Dr. Ewelina Kulikowski Ph.D.
Chief Scientific Officer
No Bio Available
Dr. Michael Sweeney M.D.
Senior Vice President of Clinical Development
No Bio Available
Mr. Donald J. McCaffrey
Co-Founder, Chairman, President, CEO & Secretary
No Bio Available

Contacts

Address
ALBERTA
Calgary
300-4820 Richard Rd SW
Contacts
+14032549252.0
www.resverlogix.com